Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Procrit, Gemzar, Camptosar At Risk Under 2005 Medicare Payment Rates, ASCO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS estimates the total drop in Medicare payment reductions for 2005 at 8%; an ASCO survey of community clinics found a 15% payment reduction. ASCO seeks legislation establishing a floor in total payments through 2006.

You may also be interested in...



Aranesp Performance Strong Heading Into "Transition" Time, Amgen Says

The company is talking with oncologists about Aranesp ahead of a switch in Medicare reimbursement in January 2005. U.S. sales for the red blood cell product were up 32% in the third quarter.

Aranesp Performance Strong Heading Into "Transition" Time, Amgen Says

The company is talking with oncologists about Aranesp ahead of a switch in Medicare reimbursement in January 2005. U.S. sales for the red blood cell product were up 32% in the third quarter.

Price Competition To Procrit Is Beginning To Stabilize, J&J Says

Recent price increases for both Procrit and Amgen’s Aranesp indicate the discount war may be over for now, J&J says. The company remains positive about the impact of the 2005 changes to Medicare Part B drug reimbursement on Procrit’s positioning within the EPO market.

Related Content

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel